As of Sep 30
| +0.30 / +2.11%|
The 1 analysts offering 12-month price forecasts for Cellular Biomedicine Group Inc have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +10.34% increase from the last price of 14.50.
The current consensus among 1 polled investment analysts is to Buy stock in Cellular Biomedicine Group Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.